Overcoming Resistance to PARP Inhibitors in BRCA-Mutated Cancers: Mechanisms and Therapeutic Strategies
Journal of Cancer · 2026-09-03 · 17 (9) · 1600-1614
DOI: 10.7150/jca.130206 ↗At a glance
Übersichtsarbeit in Journal of Cancer, published on 2026-09-03. Written by Jiahui Guo and 3 co-authors. Institution: Department of Pharmacy, Zhangjiagang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, 215600, China. Cited 1 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
The tumor suppressor genes BRCA1 and BRCA2 are essential for homologous recombination (HR) repair. Mutations in BRCA1/2 compromise HR repair efficacy, resulting in heightened susceptibility of tumor cells to poly (ADP-ribose) polymerase inhibitors (PARPi) via synthetic lethality. To date, several PARPi have been approved for BRCA-mutated and HR-deficient tumors, but acquired resistance and cumulative toxicity continue to limit their long-term clinical benefit. This narrative review offers an updated mechanistic model of PARPi action and categorizes resistance mechanisms by clinical relevance and evidentiary strength. Importantly, we distinguish between standard combination therapies in the PARPi-naïve setting and interventions explicitly tailored for PARPi-exposed or PARPi-resistant disease. Building on this distinction, we propose a biomarker-guided framework that links specific resistance phenotypes to appropriate specimen types, detection assays, and candidate interventions. Through this evidence-based clinical framework, we aim to clarify the current therapeutic landscape, improve data interpretation, and guide prospective trial design.
Subjects
Author keywords
Authors and institutions
- Department of Pharmacy, Zhangjiagang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, 215600, China.
- School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China.
- Department of Pharmacy, Taicang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Taicang, Jiangsu, 215400, China.
Cite
APA
Guo, J., Wang, Y., Li, J., & Jiang, Z. (2026). Overcoming Resistance to PARP Inhibitors in BRCA-Mutated Cancers: Mechanisms and Therapeutic Strategies. Journal of Cancer, 17(9), 1600-1614. https://doi.org/10.7150/jca.130206
Vancouver
Guo J, Wang Y, Li J, Jiang Z. Overcoming Resistance to PARP Inhibitors in BRCA-Mutated Cancers: Mechanisms and Therapeutic Strategies. Journal of Cancer. 2026;17(9):1600-1614. doi:10.7150/jca.130206
BibTeX
@article{Guo2026,
author = {Guo, Jiahui and Wang, Yilei and Li, Jie and Jiang, Zhitao},
title = {Overcoming Resistance to PARP Inhibitors in BRCA-Mutated Cancers: Mechanisms and Therapeutic Strategies},
journal = {Journal of Cancer},
year = {2026},
volume = {17},
number = {9},
pages = {1600--1614},
doi = {10.7150/jca.130206}
}
EUVIMED